Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $44.6 million versus the consensus estimate of $42.27 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.